Nonetheless, this study showed a consistent trend: immune status at the beginning and EOT were associated with patient outcomes in T-DM1 treatment, whereas immune status at the beginning and EOT were not associated with patient outcomes in T-DXd treatment for HER2-positive breast cancer, thus clearly distinguishing both treatments. The gene discussed is ERBB2; the disease is breast carcinoma.